{"transactions":[{"id":760240,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:25:45.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038966","document":"wk-form4_1780010743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038966/wk-form4_1780010743.xml","form_type":"4"}},{"id":760239,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:25:45.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":39806,"source":{"system":"sec-edgar","filing":"0001628280-26-038966","document":"wk-form4_1780010743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038966/wk-form4_1780010743.xml","form_type":"4"}},{"id":766448,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true}}],"security":"Stock Option  (Right to Buy)","published_at":"2026-05-22T20:20:46.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":1441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":1441,"derivative":{"exercise_price":298.48,"exercise_date":"2027-05-20","expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1441},"source":{"system":"sec-edgar","filing":"0001178670-26-000042","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000042/form4.xml","form_type":"4"}},{"id":766447,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-22T20:20:46.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":1446,"source":{"system":"sec-edgar","filing":"0001178670-26-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000042/form4.xml","form_type":"4"}},{"id":1127713,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:31:04.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028902","document":"wk-form4_1748907056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028902/wk-form4_1748907056.xml","form_type":"4"}},{"id":1127712,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:31:04.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on  May 30, 2026."}],"balance_after":31806,"source":{"system":"sec-edgar","filing":"0001628280-25-028902","document":"wk-form4_1748907056.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028902/wk-form4_1748907056.xml","form_type":"4"}},{"id":1152503,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2025-05-12T20:04:14.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":1558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":1558,"derivative":{"exercise_price":258.35,"exercise_date":"2026-05-08","expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":1558},"source":{"system":"sec-edgar","filing":"0001735276-25-000060","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000060/edgardoc.xml","form_type":"4"}},{"id":1152502,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-12T20:04:14.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":775,"source":{"system":"sec-edgar","filing":"0001735276-25-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000060/edgardoc.xml","form_type":"4"}},{"id":1495203,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-03T16:18:50.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":10.39,"exercise_date":"2025-05-30","expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-24-026221","document":"wk-form4_1717431521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026221/wk-form4_1717431521.xml","form_type":"4"}},{"id":1495202,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-03T16:18:50.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23806,"source":{"system":"sec-edgar","filing":"0001628280-24-026221","document":"wk-form4_1717431521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026221/wk-form4_1717431521.xml","form_type":"4"}},{"id":1509306,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2024-05-20T20:08:42.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":5228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":5228,"derivative":{"exercise_price":151.22,"exercise_date":"2025-05-16","expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":5228},"source":{"system":"sec-edgar","filing":"0001735276-24-000052","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000052/edgardoc.xml","form_type":"4"}},{"id":1784699,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-08T16:00:37.000Z","date":"2023-09-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":113636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the \"Merger Agreement\"), by and among the Issuer, Coherus BioSciences, Inc. (\"Coherus\"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus (\"Merger Sub I\"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the \"Effective Time\"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the \"First Merger\"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an \"In-the-Money Option\") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an \"In-the-Money Option\") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":0.35,"underlying":"Common Stock","underlying_shares":113636},"source":{"system":"sec-edgar","filing":"0001209191-23-048762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919123048762/doc4.xml","form_type":"4"}},{"id":1784698,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T16:00:37.000Z","date":"2023-09-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45453,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the \"Merger Agreement\"), by and among the Issuer, Coherus BioSciences, Inc. (\"Coherus\"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus (\"Merger Sub I\"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the \"Effective Time\"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the \"First Merger\"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the \"Exchange Ratio\") shares of common stock of Coherus and (ii) one contingent value right (each, a \"CVR\") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Sigal Family Investments, LLC. The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-048762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919123048762/doc4.xml","form_type":"4"}},{"id":1839268,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-07-03T21:02:43.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":933317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":933317,"derivative":{"exercise_price":0.16,"exercise_date":"2024-07-03","expiration_date":"2033-07-03","underlying":"Ordinary Shares","underlying_shares":933317},"source":{"system":"sec-edgar","filing":"0001104659-23-077668","document":"tm2320409-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923077668/tm2320409-4_4seq1.xml","form_type":"4"}},{"id":1879786,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T18:33:48.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":12054,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12054,"derivative":{"exercise_price":25.74,"exercise_date":"2024-05-22","expiration_date":"2033-05-21","underlying":"Common Stock","underlying_shares":12054},"source":{"system":"sec-edgar","filing":"0001209191-23-031840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031840/doc4.xml","form_type":"4"}},{"id":1879785,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T18:33:48.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":6027,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15806,"source":{"system":"sec-edgar","filing":"0001209191-23-031840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031840/doc4.xml","form_type":"4"}},{"id":1885137,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2023-05-19T20:06:35.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":3454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":3454,"derivative":{"exercise_price":189.87,"exercise_date":"2024-05-18","expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":3454},"source":{"system":"sec-edgar","filing":"0001735276-23-000067","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527623000067/edgardoc.xml","form_type":"4"}},{"id":1979673,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-02T21:27:44.000Z","date":"2023-03-01","kind":"purchase","acquired":true,"shares":2500,"price":22.7262,"value":56815.5,"ownership":{"direct":false,"nature":"By Sigal Family Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.595 to $22.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-23-014673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123014673/doc4.xml","form_type":"4"}},{"id":2058906,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T16:51:55.000Z","date":"2023-01-05","kind":"purchase","acquired":true,"shares":2500,"price":24.9582,"value":62395.5,"ownership":{"direct":false,"nature":"By Sigal Family Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.81 to $25.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-23-002507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123002507/doc4.xml","form_type":"4"}},{"id":2062810,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T22:00:59.000Z","date":"2023-01-04","kind":"purchase","acquired":true,"shares":2500,"price":25.2545,"value":63136.25,"ownership":{"direct":false,"nature":"By Sigal Family Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.08 to $25.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-23-001932","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123001932/doc4.xml","form_type":"4"}},{"id":2062809,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T22:00:59.000Z","date":"2023-01-03","kind":"purchase","acquired":true,"shares":2500,"price":25.597,"value":63992.5,"ownership":{"direct":false,"nature":"By Sigal Family Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.41 to $25.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001209191-23-001932","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123001932/doc4.xml","form_type":"4"}},{"id":2175166,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2022-08-24T20:08:34.000Z","date":"2022-08-22","kind":"grant","acquired":true,"shares":4456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant."}],"balance_after":4456,"derivative":{"exercise_price":217.91,"expiration_date":"2032-08-22","underlying":"Common Stock","underlying_shares":4456},"source":{"system":"sec-edgar","filing":"0001735276-22-000074","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000074/edgardoc.xml","form_type":"4"}},{"id":2216723,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-07-01T21:01:33.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":737050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":737050,"derivative":{"exercise_price":0.28,"exercise_date":"2023-07-01","expiration_date":"2032-07-02","underlying":"Ordinary Shares","underlying_shares":737050},"source":{"system":"sec-edgar","filing":"0001104659-22-076896","document":"tm2220260-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465922076896/tm2220260-3_4seq1.xml","form_type":"4"}},{"id":2236079,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:00:48.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":24000,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-036151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122036151/doc4.xml","form_type":"4"}},{"id":2256820,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T22:09:04.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":12810,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12810,"derivative":{"exercise_price":24.14,"exercise_date":"2023-05-23","expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":12810},"source":{"system":"sec-edgar","filing":"0001209191-22-031959","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031959/doc4.xml","form_type":"4"}},{"id":2256819,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T22:09:04.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":6405,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9779,"source":{"system":"sec-edgar","filing":"0001209191-22-031959","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031959/doc4.xml","form_type":"4"}},{"id":2643572,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-07-02T21:01:51.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":474385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":474385,"derivative":{"exercise_price":0.71,"exercise_date":"2022-07-01","expiration_date":"2031-07-02","underlying":"Ordinary Shares","underlying_shares":474385},"source":{"system":"sec-edgar","filing":"0001104659-21-088967","document":"tm2121284-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465921088967/tm2121284-3_4seq1.xml","form_type":"4"}},{"id":2674018,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T16:30:28.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":17700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":17700,"derivative":{"exercise_price":7.69,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":17700},"source":{"system":"sec-edgar","filing":"0001209191-21-039464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121039464/doc4.xml","form_type":"4"}},{"id":2697047,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-25T20:48:59.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":6748,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6748,"derivative":{"exercise_price":45.28,"exercise_date":"2022-05-21","expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":6748},"source":{"system":"sec-edgar","filing":"0001209191-21-035717","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035717/doc4.xml","form_type":"4"}},{"id":2697046,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T20:48:59.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":3374,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3374,"source":{"system":"sec-edgar","filing":"0001209191-21-035717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035717/doc4.xml","form_type":"4"}},{"id":3008353,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-13T23:16:17.000Z","date":"2020-07-10","kind":"grant","acquired":true,"shares":28394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option vest and become exercisable on July 10, 2021, and the remaining shares vest in 24 equal monthly installments thereafter."}],"balance_after":28394,"derivative":{"exercise_price":48.71,"expiration_date":"2030-07-09","underlying":"Common Stock","underlying_shares":28394},"source":{"system":"sec-edgar","filing":"0001209191-20-054743","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919120054743/doc4a.xml","form_type":"4/A","original_submission_date":"2020-07-14"}},{"id":3083685,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-15T00:22:51.000Z","date":"2020-07-10","kind":"grant","acquired":true,"shares":57777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option vest and become exercisable on July 10, 2021, and the remaining shares vest in 24 equal monthly installments thereafter."}],"balance_after":57777,"derivative":{"exercise_price":48.71,"expiration_date":"2030-07-10","underlying":"Common Stock","underlying_shares":57777},"source":{"system":"sec-edgar","filing":"0001209191-20-042454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919120042454/doc4.xml","form_type":"4"}},{"id":3094839,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-07-01T21:07:30.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":184258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":184258,"derivative":{"exercise_price":1.67,"exercise_date":"2021-07-01","expiration_date":"2030-07-02","underlying":"Ordinary Shares","underlying_shares":184258},"source":{"system":"sec-edgar","filing":"0001104659-20-079786","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465920079786/a4.xml","form_type":"4"}},{"id":3112046,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-12T08:00:24.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director."}],"balance_after":12000,"derivative":{"exercise_price":4.35,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-036181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120036181/doc4.xml","form_type":"4"}},{"id":3398719,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-03T16:33:44.000Z","date":"2019-10-01","kind":"grant","acquired":true,"shares":13572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer and committee fees of $9,750 which would have been paid quarterly. This option shall vest in full on December 31, 2019."}],"balance_after":13572,"derivative":{"exercise_price":1.17,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":13572},"source":{"system":"sec-edgar","filing":"0001209191-19-052219","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119052219/doc4.xml","form_type":"4"}},{"id":3467276,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-07-03T21:00:49.000Z","date":"2019-07-02","kind":"grant","acquired":true,"shares":234407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":234407,"derivative":{"exercise_price":0.61,"exercise_date":"2020-07-02","expiration_date":"2029-07-02","underlying":"Ordinary Shares","underlying_shares":234407},"source":{"system":"sec-edgar","filing":"0001104659-19-039326","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465919039326/a4.xml","form_type":"4"}},{"id":3471474,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-02T17:19:44.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":5696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was issued to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer and committee fees of $9,750 which would have been paid quarterly. This option shall vest in full on September 30, 2019."}],"balance_after":5696,"derivative":{"exercise_price":2.79,"expiration_date":"2029-07-01","underlying":"Common Stock","underlying_shares":5696},"source":{"system":"sec-edgar","filing":"0001209191-19-040466","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119040466/doc4.xml","form_type":"4"}},{"id":3499077,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T16:46:17.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director."}],"balance_after":12100,"derivative":{"exercise_price":3.69,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001209191-19-035103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119035103/doc4.xml","form_type":"4"}},{"id":3872787,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-05T16:06:01.000Z","date":"2018-07-02","kind":"grant","acquired":true,"shares":8882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 24 equal monthly installments after  May 1, 2018."}],"balance_after":8882,"derivative":{"exercise_price":16.83,"expiration_date":"2028-07-02","underlying":"Common Stock","underlying_shares":8882},"source":{"system":"sec-edgar","filing":"0000899243-18-019432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000089924318019432/doc4.xml","form_type":"4"}},{"id":3882849,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-06-26T21:00:38.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":154809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":154809,"derivative":{"exercise_price":2.18,"exercise_date":"2019-06-22","expiration_date":"2028-06-22","underlying":"Ordinary Shares","underlying_shares":154809},"source":{"system":"sec-edgar","filing":"0001104659-18-042320","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465918042320/a4.xml","form_type":"4"}},{"id":3958638,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-04-23T16:15:02.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Sigal Family Investments, LLC.  The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":45453},"source":{"system":"sec-edgar","filing":"0001209191-18-025822","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025822/doc4.xml","form_type":"4"}},{"id":3958637,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T16:15:02.000Z","date":"2018-04-23","kind":"exercise","acquired":true,"shares":45453,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Sigal Family Investments, LLC.  The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":45453,"source":{"system":"sec-edgar","filing":"0001209191-18-025822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025822/doc4.xml","form_type":"4"}},{"id":4267418,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2017-07-03T21:01:54.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":220788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.58 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount."}],"balance_after":220788,"derivative":{"exercise_price":0.75,"exercise_date":"2018-07-03","expiration_date":"2027-07-03","underlying":"Ordinary Shares","underlying_shares":220788},"source":{"system":"sec-edgar","filing":"0001104659-17-043263","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465917043263/a4.xml","form_type":"4"}}]}